

• •



2015 .

.....	3
.....	6
-10.....	6
.....	7
.....	8
.....	10
.....	15
.....	17
.....	22
.....	22
.....	23
.....	23
.....	25

**XVIII**  
» 14

2015 .

’ « ’

• ” - •

- • ” • • • • • ” -

• ” - • • • • • /

,

,

• • • • • / :

,

• • • • • / :

• • • • • EMBASE MEDLINE.

,

• • • • • ; (

• • • • • ).

:

1++	- , ( )
1+	- , ,

1-	- , ,
2++	- .
2+	-
2-	-
3	( :
4	, )

, :

- - ;
- .

, :

.

:

	, 1++ , - , , 1+, ,



( ) -

,

.

,

.

,

.

[1,2].

- ( ∴ , - )

—

,

,

,

[1,2].

**-10**

L51

L51.0

L51.1 ( - )

L51.2 [ ]

L51.8

L51.9

L27 , ,

L27.0 ,

L27.1 ,

L27.2 ,

L27.8

L27.9

. -  
 - .  
 -  
 ( , , ,  
 .), 70% . ,  
 , -  
 , -

[3].

( , ECHO,  
 Varicella-Zoster, - ), ( - *Mycoplasma*  
*pneumonia*) ,  
 ( , ,  
 .) [1,4-8]

-  
 ,  
 ( , , , ,  
 , ) .  
 ,  
 .  
 ( ), ( , , ,  
 ( ) .

1.

2.

( - ).



, , - ,  
, - .

, ( ) .

1905 . J. Jadassohn, « »,

5 :

1. ,
2. , ,
3. ,
4. ,
5. .

,  
.  
1993 ,

(BSA) [9].

4

:

1. , , ,  
3 : ,  
-  
( )
2. , , ,  
2

( ) /

3. ,

2 / .

4. ,

.

4

.

5

BSA:

1. - 10%

BSA ,

2. - 10% BSA

,

3. -

( ) 10-

30% BSA ,

.

4. ( )

30% BSA

,

5. ( )

10% BSA

.

-

，  
， ， ， ， ，  
（ — ， ）  
，  
（ ， ， ） [10].

—  
，  
3 ， （  
« 》， « 》， « 》），  
2

3 .  
， —  
， ， ，  
， ， ， —  
（ ）.

， [11].

（ ）  
，  
5% ， ，  
， ， ，  
[12].

— 2-3 ，  
，

. (

). -

( ). ,

[2].

\_\_\_\_\_ ( )

,

(39-40 ),

, , , , ,

, , .

, 2

10% [13,14].

, , , , ,

, , .

, , ,

. , ,

, , (

) (

,

). -

, - , ,

(« »).

·  
·  
,  
,  
-  
-  
( )

- , - , ·

30% , [13,14].

, 10—30%  
· [13-15]

100% , ·

·  
, ,  
, ( )  
( ) , - ).  
, -

2-3 ,

\_\_\_\_\_ (\_\_\_\_\_)

\_\_\_\_\_ [16].

( 10 ),  
14 ),  
« »).

[17,18].

.

.

---

,

,

( , , , ) ,

), ( , , , ) ,

,

.

---

( )

,

,

,

,

.

( 3 ) .

.

,

— , .

,

,

,

,

,

,

,

,

[2].

(

),

,

.

,

,

,

-

,

.

,

,

,

,

,

,

.

-

.

-

.

39-40°

-

,

.

:

-

,

,

.

.

,

,

(

)

.

(

1

3

).

-

,

[16].

,



,

,

,

.

(

),

(

),

-

.

,

,

,

.

.

-

,

,

.

,

.

---

---

---

---

,

.

1. (D) ( ) [10]:
- , , : , ,  
/ / . 15 - 18 25 2-3 ( 100 / ); / , /  
— 1-2 2% , 7-14 12,5 , 1-6 8,33 , 1-12  
6,25 , 7-  
10 ( ( 1 ).)
  - , ( ) 12 — 1 ( )  
20 (1,5 . ) 2 ( ),  
6 120 ; 6-12  
— 0,5-1 2 . : 1-3 — 1-2 . , 4-6 —  
2 . , 7-12 — 1 . : / 25 / / 2  
. — 7 - 10
  - , 10 — 50-200 1-2  
; : — 300 , — 600 ;  
5 10 — 100-200 / , 2 5 — 50-150 / , 2 —  
50-100 / . 7-10
  - , , ( ), 2 3 —  
5 2-3 , 3 7 — 10 2 , 7 12  
— 10-15 2-3 , 12 — 25 2-3 .  
— 10-15 .
  - , 12 — 1-2 (20-40 ) 3  
4 (1 .) 1 ( );  
1 12 (1 - 1 : 3-10 , 1-3 :  
10-15 , 3-12 : 15-20 , — 3 );  
25 , 7-  
10 .
  - , ( 12 30 ) — 10  
(1 2 . ) 1 . 2

12 — 5 (1/2 1 . ) 1  
7-10

• , 12 — 5 / .  
( ) 1 5 — 1,25 / , 6-11 —  
2,5 / 7-10 . 1 .

• , 6 — 10 1 5 2  
, 2-6 — 5 1 2,5 2 ( )  
2,5 2 , 6-12 — 2,5 1 7-  
10 . 6 .

• , , 6  
-5 , 2 6 — 2,5 / 7-  
10 . : 6  
, 2 .

2. (D):

• , ( ,  
- ;  
) , 12 6 — 1 2,5  
/ / , 6 — 1 2 / /  
.

3. (A) [19,20]

• , 1-2 / / . 7-  
10 .

• , 2-3 / ,  
120-150 ,  
300 .

(7-10 ) ,

• , 4 / / 2 ( 7-10 ) .

4.

:

• , (A) 10 / 6 12 [21]

5. *Mycoplasma pneumoniae*

(D): ( , ), ( ) [22,23].

6.

100-150 (D), 200 400 , (D), 100-150 (D), (1000 2 ). (D) [12]

—

( ) [24]

---

1. (D): 1%

, , .

2. (D):

• 0,1%,

• 17- 0,1%

• 0,1%.

3. :

, . (D)

4.

, , . (D)

\_\_\_\_\_ ( )

, .  
(  
) ,  
, .

\_\_\_\_\_

1.

- . ,  
, ,

2.

( ) - 3

[25].

3.

. (

4.

)( ) [25,26]

2-3 /

.

\_\_\_\_\_

- , . (D) ,

. (D)

— ,  
.(D)

:

-  
-  
-  
-

,

,

.

.

-

,

.

-

,

,

(

)

.

,

,

[1]

,

(

-

,

)

.

.

.

,

,

.

1. -
2. -
- 3.
- 4.

1. Lawrence A. Schachner, Ronald C. Hansen. *Pediatric Dermatology*, 4th Edition. Elsevier. 2011.
2. Sokumbi O, Wetter DA. Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologist. *Int J Dermatol*. 2012; 51 (8): 889-902.
3. Forman R, Koren G, Shear NH. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years' experience. *Drug Saf*. 2002; 25 (13): 965-972.
4. Schalock PC, Dinulos JG, Pace N, Schwarzenberger K, Wenger JK. Erythema multiforme due to *Mycoplasma pneumoniae* infection in two children. *Pediatr Dermatol*. 2006 Nov-Dec;23(6):546-55.
5. Tay YK, Huff JC, Weston WL. *Mycoplasma pneumoniae* infection is associated with Stevens-Johnson syndrome, not erythema multiforme (von Hebra). *J Am Acad Dermatol*. 1996 Nov;35(5 Pt 1):757-60
6. Di Lernia V, Mansouri Y. Epstein-Barr virus and skin manifestations in childhood. *Int J Dermatol*. 2013 Oct;52(10):1177-84
7. Weston WL, Brice SL, Jester JD et al. Herpes simplex virus in childhood erythema multiforme. *Pediatrics*. 1992 Jan;89(1):32-4

8. Huff JC. Erythema multiforme and latent herpes simplex infection. *Semin Dermatol.* 1992;11 (3): 207-10
9. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. *Arch Dermatol.* 1993 Jan;129(1):92-6.
10. Cre u A, Dimitriu A, Br ni teanu D, Brini teanu DE. Erythema multiforme--etiopathogenic, clinical and therapeutic aspects. *Rev Med Chir Soc Med Nat Iasi.* 2015; 119 (1): 55-61.
11. Lam NS, Yang YH, Wang LC et al. Clinical characteristics of childhood erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in Taiwanese children. *J Microbiol Immunol Infect.* 2004; 37 (6): 366-370
12. Samim F, Auluck A, Zed C, Williams PM. Erythema multiforme: a review of epidemiology, pathogenesis, clinical features, and treatment. *Dent Clin North Am.* 2013; 57 (4): 583-596.
13. . . . — .: , 2001.— 196 .
14. . . . — : , 2000.— 142
15. Tomasini C1, Derlino F, Quaglino P. From erythema multiforme to toxic epidermal necrolysis. Same spectrum or different diseases? *G Ital Dermatol Venereol.* 2014; 149 (2): 243-261
16. Lee AY. Fixed drug eruptions. Incidence, recognition, and avoidance. *Am J Clin Dermatol.* 2000; 1 (5): 277-285
17. Morelli JG, Tay YK, Rogers M et al. Fixed drug eruptions in children. *J Pediatr.* 1999; 134 (3): 365-367
18. Shah SN, Chauhan GR, Manjunatha BS, Dagrus K. Drug induced erythema multiforme: two case series with review of literature. *J Clin Diagn Res.* 2014; 8 (9): ZH01-4
19. Rasmussen JE. Erythema multiforme in children. Response to treatment with systemic corticosteroids. *Br J Dermatol.* 1976 Aug;95(2):181-6



20. Kakourou T, Klontza D, Soteropoulou F, Kattamis C. Corticosteroid treatment of erythema multiforme major (Stevens-Johnson syndrome) in children. *Eur J Pediatr.* 1997; 156 (2): 90-93
21. Tatnall FM, Schofield JK, Leigh IM. A double-blind, placebo-controlled trial of continuous acyclovir therapy in recurrent erythema multiforme. *Br J Dermatol.* 1995;132 (2) :267-270
22. Grosber M, Alexandre M, Poszepczynska-Guigné E. Recurrent erythema multiforme in association with recurrent *Mycoplasma pneumoniae* infections. *J Am Acad Dermatol.* 2007; 56 (5 Suppl): S118-119
23. Martire B, Foti C, Cassano N et al. Persistent B-cell lymphopenia, multiorgan disease, and erythema multiforme caused by *Mycoplasma pneumoniae* infection. *Pediatr Dermatol.* 2005 Nov-Dec;22(6):558-60
24. Kamanbroo D, Schmitz-Landgraf W, Czarnetski BM: Plasmapheresis in severe drug-induced toxic epidermal necrolysis. *Arch Dermatol.* 121:1548-1549 1985
25. . . . - . . . . .  
. . . . . - .  
. - 1999. - .790 - 803
26. . . . . ,  
2010, 31

BSA – Body surface area ( )

ECHO – Enteric Cytopathic Human Orphan ( )

- 
- 
- 
-

